Autonomix Medical, Inc. AMIX

Patent expands protection for catheter-based technologies enabling transvascular access, treatment guidance, adaptive treatment delivery, and real-time procedural validation beyond the lumen wall Patent reinforces Autonomix’s transvascular intervention platform across multiple nerve-targeted therapies THE WOODLANDS, TX, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted

FDA pre-submission feedback supports a Class II strategy, leveraging substantial equivalence to a previously cleared device, positioning the Company for potential initial U.S. clearance of its standalone sensing platform in approximately 15 months THE WOODLANDS, TX, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced the successful completion